Tert-butyl 4-[5,6-dichloro-1-(5-iodopentyl)benzimidazol-2-yl]piperidine-1-carboxylate | 578709-50-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: Tert-butyl 4-[5,6-dichloro-1-(5-iodopentyl)benzimidazol-2-yl]piperidine-1-carboxylate
• CAS: 578709-50-9
• 化学式: C₂₂H₃₀Cl₂IN₃O₂
• 分子量: 566.31
• InChiKey: YSLCKVLNFMLJSR-UHFFFAOYSA-N

物化性质

• 沸点：
  617.6±55.0 °C(Predicted)
• 密度：
  1.53±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  47.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Tert-butyl 4-[5,6-dichloro-1-(5-iodopentyl)benzimidazol-2-yl]piperidine-1-carboxylate 在 盐酸 、 sodium hydride 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 5,6-Dichloro-2-piperidin-4-yl-1-(5-[1,2,4]triazol-4-yl-pentyl)-1H-benzoimidazole
  参考文献：
  名称：

  Synthesis and biological evaluations of novel benzimidazoles as potential antibacterial agents

  摘要：

  A series of novel benzimidazole derivatives were synthesized via parallel solution-phase chemistry. Many of these compounds were found to inhibit the growth of Staphylococcus aureus and Escherichia coli. Several analogues exhibited low micromolar minimal inhibitory concentrations (MIC) against both Gram-positive and Gram-negative bacteria of clinical relevance and could serve as leads for further optimizations for antibacterial research. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.051
• 作为产物：
  描述：

  在 sodium hydroxide 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 Tert-butyl 4-[5,6-dichloro-1-(5-iodopentyl)benzimidazol-2-yl]piperidine-1-carboxylate
  参考文献：
  名称：

  Synthesis and biological evaluations of novel benzimidazoles as potential antibacterial agents

  摘要：

  A series of novel benzimidazole derivatives were synthesized via parallel solution-phase chemistry. Many of these compounds were found to inhibit the growth of Staphylococcus aureus and Escherichia coli. Several analogues exhibited low micromolar minimal inhibitory concentrations (MIC) against both Gram-positive and Gram-negative bacteria of clinical relevance and could serve as leads for further optimizations for antibacterial research. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.051

文献信息

• US7244847B2
  申请人：——

  公开号：US7244847B2

  公开（公告）日：2007-07-17